Cancer drug delivery最新文献_第4页

Pharmacologic studies of intra-hepatic artery chemotherapy with degradable starch microspheres. 可降解淀粉微球肝内动脉化疗的药理学研究。

Cancer drug delivery Pub Date : 1986-01-01 DOI: 10.1089/cdd.1986.3.1

C E Pfeifle, S B Howell, W L Ashburn, R M Barone, J J Bookstein

{"title":"Pharmacologic studies of intra-hepatic artery chemotherapy with degradable starch microspheres.","authors":"C E Pfeifle, S B Howell, W L Ashburn, R M Barone, J J Bookstein","doi":"10.1089/cdd.1986.3.1","DOIUrl":"https://doi.org/10.1089/cdd.1986.3.1","url":null,"abstract":"The effect of degradable starch microspheres (DSM) on the pharmacokinetics of 4 drugs administered via the hepatic artery was studied in 5 patients with colon carcinoma metastatic to the liver. The 4 drugs were 99m-technetium diethylenetriamine pentaacetic acid (99mTc-DTPA), an agent which is not metabolized in the liver, and floxuridine, doxorubicin, and mitomycin, agents which undergo hepatic metabolism to varying extents. DSM transiently decreased arterial blood flow to normal liver an average of 64% and to hepatic tumor an average of 78%. DSM increased tumor exposure to DTPA by a mean of 1.71-fold, and increased hepatic exposure by 1.46-fold, but did not affect total plasma exposure. In contrast, DSM did reduce total plasma exposure to floxuridine by a mean of 34%, and to mitomycin by 20%. No information was available on the effect of DSM on plasma doxorubicin levels which never exceeded the limits of detection. Variation in the injection rate of DSM did not appear to influence the relative advantages produced in tumor or plasma AUCs. The estimated increase in tumor exposure produced by DSM was 3.8-fold for floxuridine, and 3.0-fold for mitomycin. These results reflect the differences in extent of hepatic metabolism of these agents, and agree closely with predictions made from mathematical models. Although DSM improved the therapeutic index, the increase in tumor exposure was insufficient to produce significant tumor regression.","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"3 1","pages":"1-14"},"PeriodicalIF":0.0,"publicationDate":"1986-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1986.3.1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14073831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Reversal of intrinsic resistance to adriamycin in normal cells by verapamil. 维拉帕米逆转正常细胞对阿霉素的内在耐药性。

Cancer drug delivery Pub Date : 1986-01-01 DOI: 10.1089/cdd.1986.3.251

T J Lampidis, A Krishan, L Planas, H Tapiero

引用次数: 33

Peritoneal access for intracavitary chemotherapy. 腔内化疗的腹膜通路。

Cancer drug delivery Pub Date : 1986-01-01 DOI: 10.1089/cdd.1986.3.157

S B Howell, C E Pfeifle

引用次数: 6

Potentiation of hydroxyurea cytotoxicity by iron-chelating agent in murine tumor models in vitro. 铁螯合剂对体外小鼠肿瘤模型羟基脲细胞毒性的增强作用。

Cancer drug delivery Pub Date : 1986-01-01 DOI: 10.1089/cdd.1986.3.173

K Satyamoorthy, M P Chitnis, S G Pradhan

引用次数: 4

Abstracts. First International Congress on Neo-Adjuvant Chemotherapy. November 6-9, 1985, Paris, France. 摘要。首届新辅助化疗国际大会。1985年11月6日至9日，法国巴黎。

Cancer drug delivery Pub Date : 1986-01-01

引用次数: 0

Selective killing of normal and neoplastic human B cells with anti-CD19- and anti-CD22-ricin A chain immunotoxins. 用抗cd19 -和抗cd22 -蓖麻毒素A链免疫毒素选择性杀伤正常和肿瘤人B细胞。

Cancer drug delivery Pub Date : 1986-01-01 DOI: 10.1089/cdd.1986.3.261

R D May, E S Vitetta, G Moldenhauer, B Dörken

引用次数: 35

1-beta-D-arabinofuranosylcytosine conjugates of thioether phospholipids as a new class of potential antitumor drugs. 1- β - d -阿拉伯糖醛基胞嘧啶缀合物硫醚磷脂作为一类潜在的新型抗肿瘤药物。

Cancer drug delivery Pub Date : 1986-01-01 DOI: 10.1089/cdd.1986.3.101

C I Hong, A J Kirisits, D J Buchheit, A Nechaev, C R West

{"title":"1-beta-D-arabinofuranosylcytosine conjugates of thioether phospholipids as a new class of potential antitumor drugs.","authors":"C I Hong, A J Kirisits, D J Buchheit, A Nechaev, C R West","doi":"10.1089/cdd.1986.3.101","DOIUrl":"https://doi.org/10.1089/cdd.1986.3.101","url":null,"abstract":"Three 1-beta-D-arabinofuranosylcytosine (ara-C) conjugates of 1-S-alkyl-phospholipids (thioether phospholipids) were tested for their antitumor efficacies against L1210 and P388 leukemia in mice. These include 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-rac-1-S-hexadecyl-2-0-palmitoyl-1-thioglycerol (ara-CDP-beta-palmitoyl-DL-thiochimyl alcohol, I), ara-CDP-rac-1-S-octadecyl-2-0-palmitoyl-1-thioglycerol (ara-CDP-beta-palmitoyl-DL-thiobatyl alcohol, II), and ara-CDP-rac-1-S-octadecyl-2-0-hexadecyl-1-thioglycerol (ara-CDP-beta-cetyl-DL-thiobatyl alcohol, III). Conjugates I and II produced significant increase in life span (293-379%) and longterm survivors among mice bearing i.p. implanted L1210 lymphoid leukemia at a total dose of 400 mg (389-400 mumol)/kg. Conjugate II also displayed a strong antitumor activity against i.c. implanted L1210 leukemia in mice with an ILS range of 160-200% at a total dose of 300-450 mg (292-438 mumol/kg. Significant schedule dependency was not observed when the conjugates were administered i.p. once daily with following schedules: qd l; 1,5, 9; 1-5; and 1-9, but single doses typically produced the best effects. The i.p. administration of conjugate II gave the best results on survival of i.p. inoculated L1210 leukemic mice, then followed by the s.c. and i.m. treatments. The i.v. treatment produced a lower activity than the others. Conjugate II also exhibited a strong antitumor activity against i.p. implanted P388 leukemia in mice with ILS values of greater than 255-greater than 329% with 3-5 45-day survivors at a total dose of 300-500 mg (292-486 mumol)/kg (qd 1 or 1-5). The new conjugates I and II displayed a comparable or somewhat higher activity than the previous diacyl and 1-0-alkyl analogs.","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"3 2","pages":"101-13"},"PeriodicalIF":0.0,"publicationDate":"1986-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1986.3.101","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14827808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 17

131-I coupled to monoclonal antibodies as therapeutic agents for neuroectodermally derived tumors: fact or fiction? 131-I偶联单克隆抗体作为神经外胚层源性肿瘤的治疗剂:事实还是虚构?

Cancer drug delivery Pub Date : 1986-01-01 DOI: 10.1089/cdd.1986.3.25

J T Kemshead, D H Jones, L Lashford, J Prichard, I Gordon, F Breatnach, H B Coakham

引用次数: 25

Intraperitoneal bleomycin for ventriculoperitoneal spread of a hypothalamic astrocytoma. 下丘脑星形细胞瘤脑室-腹膜扩散的腹腔注射博来霉素。

Cancer drug delivery Pub Date : 1986-01-01 DOI: 10.1089/cdd.1986.3.205

K L Saving, B F Kimler, T S Vats

引用次数: 6

The effect of amitriptyline on the central nervous system penetration of methotrexate. 阿米替林对甲氨蝶呤渗透中枢神经系统的影响。

Cancer drug delivery Pub Date : 1986-01-01 DOI: 10.1089/cdd.1986.3.219

R L Heideman, F M Balis, S Zimm, C M Lester, D G Poplack

引用次数: 3